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Abstract
Background: Epidermal growth factor receptor (EGFR) mutation is strongly associated with the therapeutic effect
of tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer (NSCLC). Nevertheless, tumor tissue
that needed for mutation analysis is frequently unavailable. Body fluid was considered to be a feasible substitute
for the analysis, but arising problems in clinical practice such as relatively lower mutation rate and poor clinical
correlation are not yet fully resolved.
Method: In this study, 50 patients (32 pleural fluids and 18 plasmas) with TKIs therapy experience and with direct
sequencing results were selected from 220 patients for further analysis. The EGFR mutation status was re-evaluated
by Amplification Refractory Mutation System (ARMS), and the clinical outcomes of TKIs were analyzed
retrospectively.
Results: As compared with direct sequencing, 16 positive and 23 negative patients were confirmed by ARMS, and the
other 11 former negative patients (6 pleural fluids and 5 plasmas) were redefined as positive, with a fairly well clinical
outcome (7 PR, 3 SD, and 1 PD). The objective response rate (ORR) of positive patients was significant, 81.3% (direct
sequencing) and 72.7% (ARMS) for pleural fluids, and 80% (ARMS) for plasma. Notably, even reclassified by ARMS, the
ORR for negative patients was still relatively high, 60% for pleural fluids and 46.2% for plasma.
Conclusions: When using body fluids for EGFR mutation analysis, positive result is consistently a good indicator for
TKIs therapy, and the predictive effect was no less than that of tumor tissue, no matter what method was
employed. However, even reclassified by ARMS, the correlation between negative results and clinical outcome of
TKIs was still unsatisfied. The results indicated that false negative mutation still existed, which may be settled by
using method with sensitivity to single DNA molecule or by optimizing the extraction procedure with RNA or CTC
to ensure adequate amount of tumor-derived nucleic acid for the test.
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Introduction
Lung cancer causes over 1 million deaths per year
worldwide, making it the major source of cancer-related
deaths [1].There has been progress made in therapeutic
strategies for lung cancer, but the 5-year survival rate is
still only about 15% [2]. Treatment strategies for lung
cancer have changed dramatically with the recent dis-
covery that a proportion of non-small cell lung cancers
(NSCLC) harbor activating mutations in the epidermal
growth factor receptor (EGFR)g e n e[ 3 , 4 ] ,a n dt h a tt h e
mutated EGFR proteins are particularly susceptible to
inhibition by small-molecule tyrosine kinase inhibitors
(TKIs) Gefitinib and Erlotinib [5-9].
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guidelines of NSCLC, TKIs has been revised as first line
therapy according to the latest randomized phase III stu-
dies such as IPASS, First-SIGNAL, WJTOG3405, OPTI-
MAL, and the presence of EGFR-activating mutation
represents critical biological factor for proper patient
selection [5-11]. As a result, EGFR mutations analysis has
become a routine molecular test in many Chinese hospi-
tals, and direct sequencing is the most frequently used
method because it is readily available and relatively inex-
pensive to use as compared with assays of real-time PCR
such as TaqMan probes, Amplification Refractory Muta-
tion System (ARMS) and High Resolution Melting (HRM).
It is well known that the optimal DNA resource for
EGFR mutation analysis is tumor tissue. Unfortunately,
because most of the NSCLC patients were at the
advanced stage and inoperable, sufficient tumor tissue
was not readily available. For example, in IPASS study,
only 36% (437/1217) of the patients had biopsied tissue
suitable for testing, while in INTEREST study, the ratio is
only 20% (297/1466) [5,12]. On the contrary, the sam-
pling of body fluid such as pleural fluid and plasma is
usually easy, less invasive, and repeatable, which are con-
sidered to be a feasible genomic DNA resources [13-18].
Nevertheless, the mutation test procedure using body
fluids still needs to be optimized, standardized and
validated.
In our hospital, patients who couldn’t provide sufficient
tumor tissues preferred to choose body fluids for EGFR
mutation analysis, but two problems were found in our
practice when direct sequencing was used. The first one
was that the overall mutation rate was pretty lower than
the average rate of Asian ethnic detected by sequencing
(30-40%) [11], the second one was that quite a few
patients response well with the TKIs therapy although
their results of the mutation test are negative. We
inferred that the low sensitivity of sequencing may result
in the two problems. In order to verify this speculation,
we selected 50 patients with TKIs therapy experience
from the patients who joined the EGFR mutation analysis
using body fluids, re-evaluated the EGFR mutation status
of the extracted DNA by ARMS, a method with sensitiv-
ity of 1%, and analyzed the clinical outcome of TKIs
retrospectively.
We found that ARMS could improve the mutation
detection rate and the mutation positive patients
responded well with TKIs therapy, but the correlation
between mutation negative patients and TKIs therapy
was still unsatisfactory. The results indicate that sensi-
tivity of the method was not all the answers for the pro-
blems. We hypothesized that, as an alternative solution,
the extraction procedure of nucleic acid should also be
taken into consideration. The results of this study were
reported in the present manuscript.
Materials and methods
Sample collection and processing
EGFR sequencing for exon 19 and 21 is one of the rou-
tine tests for NSCLC patients who want to initiate TKIs
therapy in our hospital. The informed consent was
obtained from each patient prior to the test. Pleural
fluid samples were used as alternative clinical specimen
for patients who couldn’t provide sufficient tumor tissue.
For patients who couldn’t provide tumor tissue and
pleural fluid, plasmas were used as an alternate. DNA
was extracted from 400 μL supernatant of the pleural
f l u i do rp l a s m ab yQ I A a m pD N AB l o o dM i n ik i t( Q i a -
gen, Hilden, Germany) and eluted with 50 μLH 2O. The
extracted DNA was stored at -20°C until used.
EGFR exon 19 and 21 were amplified by polymerase
chain reaction (PCR) using nested primer (Table 1) with
Ex Taq polymerase (Takara, Tokyo, Japan). The first
cycle of amplifications were performed using a 5 min
initial denaturation at 95°C; followed by 30 cycles of 45
s at 95°C, 45 s at 54°C, and 1 min at 72°C; and a 6 min
final extension at 72°C. Production of the first cycle was
amplified in the secondary cycle using same condition
as first one. The final products were cleared and
sequenced with the internal primers using ABI PRISM
3730 DNA Analyser (Applied Biosystems, Foster City,
CA, USA).
Patients were eligible for inclusion in the study for
further analysis if they fit criteria as follow: ①With defi-
nite results of sequencing; ②The extracted DNA was of
good quality and sufficient for extra test; ③With TKIs
therapy experience and corresponding evaluation. The
study was approved by the ethical committees of
Affiliated Hospital of Academy of Military Medical
Sciences.
The patients’ DNA was re-tested by using ADx EGFR
Mutations Detection Kit (Amoy Diagnostics, Xiamen,
China), which has received State Food and Drug
Table 1 the nested primer
Sense Antisense
19 exon outer AAATAATCAGTGTGATTCGTGGAG GAGGCCAGTGCTGTCTCTAAGG
19 exon inner GTGCATCGCTGGTAACATCC TGTGGAGATGAGCAGGGTCT
21 exon outer GCAGCGGGTTACATCTTCTTTC CAGCTCTGGCTCACACTACCAG
21 exon inner GCTCAGAGCCTGGCATGAA CATCCTCCCCTGCATGTGT
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mainland China recently. The kit used the principle of
Amplified Refractory Mutation System (ARMS) and cov-
ered the 29 EGFR mutation hotspots from exon 18 to
21. The assay was carried out according to the manufac-
turer’s protocol with the MX3000P (Stratagene, La Jolla,
USA) real-time PCR system. A positive or negative
result could be reached if it met the criterion that was
defined by the manufacturer’s instruction. The results of
ADx-AMRS were compared with those of direct
sequencing.
Treatment and evaluation
All the patients enrolled in the study had experience of
TKIs therapy (Gefitinib or Erlotinib), although some of
them were defined as mutation negative. The drugs were
administered according to the manufacturer’s instruction.
TKIs therapy was not stopped until disease progression,
unacceptable toxicity, or patient refusal happened (which-
ever was sooner). After the discontinuation of TKIs treat-
ment, the patients were treated according to standard
clinical practice at the discretion of the investigators.
Efficacy was assessed with computed tomography (CT)
scans every 4 weeks until discontinuation or as clinically
indicated. Responses were defined and categorized accord-
ing to Response Evaluation Criteria in Solid Tumors
(RECIST). All partial and complete responses were con-
firmed at least 4 weeks later with repeated imaging and a
designation of stable disease required lack of progression
for 8 weeks or more.
Statistical analysis
Samples were examined to determine whether a statisti-
cally significant difference existed regarding variations in
EGFR mutations between method of DNA sequencing and
ADx-ARMS by the McNemar’s test. The relationship
between EGFR mutation and clinical outcome was exam-
ined by Fisher’s exact test. Progression-free survivals (PFS)
after TKIs therapy were analyzed by the Kaplan-Meier
method, and were compared between groups by the log-
rank test. The statistical analysis was carried out by using
SAS software version 9.1.3 (SAS Institute, Inc., Cary, NC,
USA).
Results
Characteristics of patients and samples
From December in 2008 to November in 2010, 220
patients joined the EGFR mutation analysis using body
fluids since sufficient tumor tissues were unavailable after
routine pathological examination was done. Among
them, 142 were pleural fluids, and 78 were plasma. With
direct sequencing, the corresponding mutation rate is
23.2% and 5.1% respectively (Table 2), lower than the
average rate of Asian ethnic detected by sequencing on
tumor tissues (30-40%) [11]. In addition, some mutation
negative patients received TKIs therapy regardless the
mutation status given the poor sensitivity of DNA
sequencing and were found with good outcome (data not
shown).
We inferred that the low sensitivity of sequencing may
result in the two problems. In order to verify this specu-
lation, we tried to re-evaluate the EGFR mutation status
of the extracted DNA by ARMS, a method with sensitiv-
ity of 1%. 50 patients were selected from the 220
patients according to the criteria mentioned in material
and method part for further analysis. The samples
included 32 pleural fluids and 18 plasmas. All the
patients were Chinese and at the stage of IIIB or IV.
The median age was 56.2 years (range, 31-77 years), and
there were 32 males (64%) and 18 females (36%). The
histological and/or cytological diagnosis for all the
patients was adenocarcinoma. All the patients were trea-
t e dw i t hT K I sa n de v a l u a t e df o rt h er e s p o n s e ,3 2
patients with Partial Response (PR), 7 with Stable Dis-
ease (SD), 11 with Progressive Disease (PD).
EGFR mutation status and clinical outcome
The EGFR mutation status and clinical outcome for
each patient was shown in Additional file 1. By direct
sequencing, 16 samples were mutation positive and the
other 34 were negative; By ADx-ARMS, 16 mutation
positive and 23 negative samples were confirmed. How-
ever, 11 former negative samples (6 pleural fluids and 5
plasmas) were redefined as mutation positive. As shown
in Table 3, for pleural fluid samples, ADx-ARMS was
more sensitive than direct sequencing (c
2 =4 . 1 7P =
0.0412). Nevertheless, the difference disappeared for
plasma (Table 4, c
2 =3 . 2P = 0.0736), which might be
caused by small number of the samples.
Table 2 Mutation rate for different kind of body fluid
samples in our clinical practice using sequencing
Pleural fluid Plasma Total
Total 142 78 220
19-del 18 2 20
L858R 15 2 17
Mutation rate (%) 23.2 5.1 16.8




- 0 10 10
Total 16 16 32
c
2 = 4.17 P = 0.0412
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both 19 del and L858R mutation, 4 with both 19 del
and T790M mutation, and 1 with both L858R and
L861Q or S768I (The two spots were designed in one
tube, we could not differentiate it at that time). The
representative results were showed in Figure 1.
Comparison of the clinical evaluation
The comparison of the clinical evaluation was shown in
Table 5. The therapeutic effect of TKIs was significant
for the mutation positive patients. For pleural fluid sam-
p l e s ,t h eo b j e c t i v er e s p o n s er a t e( O R R )o ft h e1 6
patients who were assessed as mutation positive by
direct sequencing was 81.3% (13 PR, 2 SD, 1 PD), while
the ORR of the 22 mutation positive patients detected
b yA D x - A R M Sw a s7 2 . 7 %( 1 6P R ,5S D ,1P D ) ,n o




- 0 13 13
Total 0 18 18
c
2 = 3.2 P = 0.0736
Figure 1 Representative result for sequencing and ADx-ARMS. A and E: No.36 patient 19 exon negative by sequencing but positive by ADx-
ARMS. C and F: No.34 patient 21 exon negative by sequencing but positive by ADx-ARMS. B: No.13 patient 19 exon 746-751 del D: No.06 patient
21 exon L858R mutation
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0.706). For plasma samples, because none was defined
as mutation positive by direct sequencing, the ORR was
unavailable. However, regarding the 5 mutation positive
patients redefined by ADx-ARMS, the ORR was 80% (4
PR, 1 PD). Although the ORR of mutation negative
patients seemed lower than that of mutation positive
one, statistical analysis showed no difference. For pleural
fluid samples with direct sequencing used, the ORR for
mutation positive and negative patients was 81.3% and
56.3%, respectively (P = 0.2524). For pleural fluids sam-
ples with ADx-ARMS used, the ORR for mutation posi-
tive and negative patients was 72.7% and 60%,
respectively (P = 0.6828). For plasma samples with
ADx-ARMS used, the ORR for mutation positive and
negative patients was 80% and 46.2%, respectively (P =
0.3137). Even reclassified by a more sensitive method,
the ORR for mutation negative patients was still rela-
tively high, which was 60% for pleural fluid samples and
46.2% for plasma samples. Besides, as it was shown in
Additional file 2, no difference was found in progres-
sion-free survival (PFS) among mutation positive and
negative patients, no matter defined by sequencing or by
ARMS. These results indicated that there might still be
false negative mutations in these samples.
Discussion
Although it has been well recognized that EGFR muta-
tion is strongly associated with the therapeutic effect of
TKIs in NSCLC patients, most patients could not provide
the tumor tissues that needed for the mutation test
[5,12]. Prior literatures indicate that it is feasible to use
the free DNA in body fluid such as pleural fluid and
plasma as alternative clinical specimen for EGFR muta-
tion analysis [13-18], but the procedure still needs to be
optimized, standardized and validated.
The major finding of our research was that, when body
fluid was used as substitute for EGFR mutation detection,
the positive result was a good indicator for TKIs therapy,
no matter it was detected by direct sequencing or ARMS.
For patients who provided pleural fluid, the ORR of the
16 mutation positive patients defined by direct sequen-
cing was 81.3%. When ARMS was used, 6 more patients
were defined as mutation positive, with the ORR of the
22 patients at 72.7%. For patients who provided plasma, 5
mutation positive patients were detected only by ARMS,
with the ORR at 80%. Generally, our result was consis-
tent with that of OPTIMAL and IPASS research, both
using tumor tissue for EGFR mutation analysis [5,9]. The
ORR for mutation positive patients in OPTIMAL using
direct sequencing was 83%, higher than that of IPASS
using ARMS strategy (71.2%). Interestingly, such differ-
ence also occurred in our study using pleural fluid sam-
ples (81.3% Vs 72.7%). The results implied that, more
sensitive methods such as ADx-ARMS may find more
positive patients, but for them, mutative cells may repre-
sent a minority of the whole tumor, which may influence
the final clinical outcome of TKIs. The explanation is
consistent with the work of Qing Zhou et al. which
found that the relative EGFR mutation abundance could
predict benefit from EGFR-TKIs treatment for advanced
NSCLC [19]. Our data emphasized that, for mutation
positive results, the predictive effect of body fluid was no
less than that of tumor tissue.
As considered for the two problems mentioned above,
our research agreed with former reports that more sensi-
tive method such as ARMS would be one of the feasible
solutions [14,20]. Compared with direct sequencing,
ADx-ARMS assay found 18.8% (6/32) and 27.8% (5/18)
more patients to be mutation positive for pleural fluid
and plasma, respectively. Direct sequencing is currently
the routine method used to detect EGFR mutations. The
Table 5 Comparison of the clinical evaluation
Pleural fluid Plasma
Sequencing ADx-ARMS Sequencing ADx-ARMS
Mutation
positive
Number (%) 16(50%) 22(68.8%) 0 5(27.8%)







Mutation negative Number (%) 16(50%) 10(31.2%) 18(100%) 13(72.2%)







PR = Partial Response; SD = Stable Disease; PD = Progressive Disease; ORR = Objective response rate
Between a and b, P = 0.2524; Between c and d, P = 0.6828; Between e and f, P = 0.3137; Between a and c, P = 0.706
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but the procedure is complicated and time-consuming.
Meanwhile, the sensitivity of sequencing is about 30%,
which tends to cause false negative result [21]. Given the
poor sensitivity of DNA sequencing, many patients and
physicians opt to start TKIs treatment even if the sequen-
cing results were negative for EGFR mutation. If the
tumor does not contain activating mutations on EGFR,
treatment with TKIs will most likely be ineffective. In our
study, 11 former negative patients (6 pleural fluids, 5
plasmas) defined by sequencing were proved to be posi-
tive at last, and the clinical outcome for them was quite
satisfactory. If the treatment plan was made according to
the result of direct sequencing, those patients may lose
the chance of TKIs therapy.
Besides, by using ARMS, we also found 7 samples
which harbouring double mutations (2 patients with 19
del and L858R, 1 with L858R and L861Q or S768I, 4
with 19 del and T790M). The clinical evaluations for
the former 3 patients were all PR. This result was con-
sistent with the study of Zhang et al. [22] which showed
that patients with double activating mutations involving
both exons 19 and 21 tend to respond well to TKIs and
the sensitivity to TKIs was enhanced compared with
either single mutant. As demonstrated by Qing Zhou et
al. that the relative EGFR mutation abundance could
predict benefit from EGFR-TKIs treatment [19], we
hypothesized that the clinical benefits (3PR, 1SD) of the
4 patients which harbouring both 19 del and T790M
may be owing to the dominant composition in 19 del.
Notably, even reclassified by ARMS, no difference was
found in PFS among mutation positive and negative
patients, the ORR for negative patients was still rela-
tively high, 60% for pleural fluids and 46.2% for plasma,
higher than that of IPASS (1.1%) and First-SIGNAL
(25.9%) research [5,6]. Taking into consideration that all
the patients in our research were adenocarcinoma, the
well known type of lung cancer that can get maximum
benefit from TKIs therapy, and the low abundance of
DNA in body fluid, the results indicated that there
might still be false negative mutations in these samples.
We presumed that the phenomenon can be explained in
two aspects.
Firstly, the sensitivity of ARMS is 1%, nevertheless, if
the abundance of the mutation DNA was below this
limitation, false negative results were inevitable. Prior
literature indicated that, using ARMS for plasma sam-
ples, the false negative rate was still relatively high,
which was about 30% as compared with tumor tissue
[13,23]. Recently, Yung TK et al. reported a method
named Microfluidics Digital PCR, which could detect a
single-mutant DNA molecule and precisely determine
the quantities of mutant and wild-type sequences. By
using this method, the sensitivity and specificity of
plasma EGFR mutation analysis reached 92% and 100%
respectively, as compared with the sequencing results of
tumor samples [18]. This method may be more suitable
than ARMS for EGFR mutation analysis using body
fluid samples, but it is not readily available now and
more stringent clinical evidence is still needed in the
future.
Secondly, regardless of the sensitivity of detection
method, if tumor-derived DNA was not contained in
the body fluid sample, the mutation analysis was
obviously in vain.
For pleural fluid samples, it is well recognized that cell
pellets could be used to ensure tumor cells was con-
tained in the sample. Nevertheless, in a significant pro-
portion of patients (30-40%), the yield of malignant cells
from thoracentesis is inadequate for cytological and
molecular diagnostic testing. We used cell-free pleural
fluids in this study because it is abundant. Meanwhile,
prior literature demonstratedt h a tw h e ns e n s i t i v eg e n o -
typing assays was used, cell-free pleural fluid could pro-
vide the same mutational information as pleural effusion
cells [15]. The problem is that, when cell-free pleural
fluid was used, it was impossible to precisely evaluate
whether the tumor-derived DNA was adequately con-
tained, since the extracted free DNA arises not only
from tumor cells, but also from the necrotic or apopto-
tic nontumor cells. Recently, free RNA in pleural fluid
as a favouring material for EGFR mutation analysis was
attracting more and more attention. The high EGFR
mutation rate of free RNA in pleural effusion has been
reported in the article by Wu et al. [24]. Later on, the
same research group found out that the mutation-detec-
tion yield of sequencing from RNA was coupled with
the superior prediction of clinical efficacy to first-line
TKIs [25]. The explanation was that, contaminated non-
tumor cells within pleural fluid may have no or lower
EGFR expression, using RNA instead of genomic DNA
as the source for EGFR mutation analysis could mini-
mize the influence of nontumor cells.
For blood samples, most reports used plasma rather
than cell pellets for mutation analysis, because tumor
cells in the blood are rare as compared with the cells of
hematopoietic lineages. The documented sensitivity of
plasma varied from 33% to 100%, which may be resulted
from various detection methods or from different
patients enrolled [17,18,23,26,27]. But using plasma
encounter the same problem as using cell-free pleural
fluid, namely, it is impossible to precisely evaluate
whether the tumor-derived DNA was adequately con-
tained. The characterization of circulating tumor cell
might resolve the problem ultimately, since it is ascer-
tain that the test was done on tumor cells. In the study
by Maheswaran et al, there were 12 patients for whom
specimens of the primary tumor, CTCs, and plasma
Liu et al. Journal of Experimental & Clinical Cancer Research 2011, 30:111
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typing of CTCs appeared to be more sensitive than
plasma (92% Vs 33%, P= 0.009) [27]. The main problem
now is that the technology of CTC enrichment still
needs to be standardized and generalized. In recent
years, tremendous efforts have been made on CTC
detection and characterization [28,29]. In the near
future, EGFR mutation analysis on CTC may become a
reality in the routine clinical practice.
Our study had two limitations, which hindered us
from verifying the hypothesis mentioned above. First,
although we and others have demonstrated that body
fluid is feasible [13-18], analysis for EGFR mutations
with DNA extracted from tumor tissue remains the gold
standard. Nevertheless, since all the patients enrolled in
this study couldn’t provide sufficient tumor tissue after
routine pathological examination was done, the muta-
tion status of the tumor tissue were not available and
we could not testify whether there were still false nega-
tive results left after the extracted DNA were re-exam-
ined by ARMS. Second, although it is necessary to re-
extract the nucleic acid with an optimized procedure by
RNA or CTC, and then, to compare the mutation analy-
sis with current study, the original body fluid samples of
the patients were not preserved after the mutation ana-
lysis was done, the comparison could not be carried out.
In order to address the two issues above, we had set a
new research plan and the patients were now under
enrolling.
Conclusions
In conclusion, our finding suggested that, when body
fluids were used for EGFR mutation analysis, positive
result is consistently a good indicator for TKIs therapy,
and the predictive effect was no less than that of tumor
tissue, no matter what method was employed. Conver-
sely, for negative result, we should be highly cautious
due to its poor correlation with the response of TKIs
therapy. The problem may be settled by using method
with sensitivity to single DNA molecule such as Digital
PCR or by optimizing the extraction procedure with
RNA or CTC to ensure adequate amount of tumor-
derived nucleic acid for the test.
Additional material
Additional file 1: EGFR mutation status and clinical outcome for
each patient. The file contains the EGFR mutation status (detected by
sequencing and ARMS) and the clinical outcome (evaluation and PFS) for
each patient.
Additional file 2: Kaplan-Meier analysis for PFS. The file contains
Kaplan-Meier analysis for PFS in 3 categories of patients: pleural fluid
samples using sequencing, pleural fluid samples using ARMS, plasma
samples using ARMS.
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